nach oben

Pituitary

Erschienen in:

01.06.2008

Drugs and HPA axis

verfasst von: Alberto Giacinto Ambrogio, Francesca Pecori Giraldi, Francesco Cavagnini

Erschienen in: Pituitary | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

This paper outlines the interferences of the most widely used drugs with hypothalamo-pituitary-adrenal function and the related laboratory parameters, with the purpose of providing practical help to clinicians during testing for hypo- or hypercortisolemic states.

Afandi B, Toumeh MS, Saadi HF (2003) Cushing’s syndrome caused by unsupervised use of ocular glucocorticoids. Endocr Pract 9:526–529PubMed

Chiang MY, Sarkar M, Koppens JM, Milles J, Shah P (2006) Exogenous Cushing’s syndrome and topical ocular steroids. Eye 20:725–727. doi:10.1038/sj.eye.6701956 PubMedCrossRef

Pessanha TM, Campos JM, Barros AC, Pone MV, Garrido JR, Pone SM (2007) Iatrogenic Cushing’s syndrome in a adolescent with AIDS on ritonavir and inhaled fluticasone. Case report and literature review. AIDS 21(4):529–532PubMedCrossRef

Main KM, Skov M, Sillesen IB et al (2002) Cushing’s syndrome due to pharmacological interaction in a cystic fibrosis patient. Acta Paediatr 91:1008–1011. doi:10.1080/080352502760272759 PubMedCrossRef

De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J (2003) Inhaled budesonide induced Cushing’s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros 2:72–75. doi:10.1016/S1569-1993(03)00022-5 PubMedCrossRef

Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN (2004) Cushing’s syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 38:46–49. doi:10.1345/aph.1D222 PubMedCrossRef

Halverstam CP, Vachharajani A, Mallory SB (2007) Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. Pediatr Dermatol 24:42–45PubMed

Ermis B, Ors R, Tastekin A, Ozkan B (2003) Cushing’s syndrome secondary to topical corticosteroids abuse. Clin Endocrinol (Oxf) 58:795–796. doi:10.1046/j.1365-2265.2003.18021.x CrossRef

Abma EM, Blanken R, De Heide LJ (2002) Cushing’s syndrome caused by topical steroid therapy for psoriasis. Neth J Med 60:148–150PubMed

10.

Hopkins RL, Leinung MC (2005) Exogenous Cushing’s syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 34:371–384. doi:10.1016/j.ecl.2005.01.013 PubMedCrossRef

11.

Güven A, Gülümser O, Ozgen T (2007) Cushing’s syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab 20:1173–1182PubMed

12.

Loli P, Berselli ME, Tagliaferri M (1986) Use of ketoconazole in the treatment of Cushing’s syndrome. J Clin Endocrinol Metab 63:1365–1371PubMed

13.

Mistraletti G, Donatelli F, Carli F (2005) Metabolic and endocrine effects of sedative agents. Curr Opin Crit Care 11:312–317. doi:10.1097/01.ccx.0000166397.50517.1f PubMedCrossRef

14.

Absalom A, Pledger D, Kong A (1999) Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 54:861–867. doi:10.1046/j.1365-2044.1999.01003.x PubMedCrossRef

15.

Bertagna X, Escourolle H, Pinquier JL et al (1994) Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab 78:375–380. doi:10.1210/jc.78.2.375 PubMedCrossRef

16.

Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF (2006) Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31:628–636. doi:10.1038/sj.npp.1300884 PubMedCrossRef

17.

Pomara N, Hernando RT, de la Pena CB, Sidtis JJ, Cooper TB, Ferris S (2006) The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer’s disease. Neurochem Res 31:585–588. doi:10.1007/s11064-006-9055-5 PubMedCrossRef

18.

Heikinheimo O, Ranta S, Grunberg S, Lähteenmäki P, Spitz IM (1997) Alterations in the pituitary-thyroid and pituitary-adrenal axes – consequences of long-term mifepristone treatment. Metabolism 46:292–296. doi:10.1016/S0026-0495(97)90256-0 PubMedCrossRef

19.

Díez JJ, Iglesias P (2007) Pharmacological therapy of Cushing’s syndrome: drugs and indications. Mini Rev Med Chem 7:467–480. doi:10.2174/138955707780619653 PubMedCrossRef

20.

Steptoe A, Ussher M (2006) Smoking, cortisol and nicotine. Int J Psychophysiol 59:228–235. doi:10.1016/j.ijpsycho.2005.10.011 PubMedCrossRef

21.

Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL (1996) Hormonal responses to d- and d,l-fenfluramine in healthy human subjects. Neuropsychopharmacology 15:595–607. doi:10.1016/S0893-133X(96)00133-9 PubMedCrossRef

22.

Schurmeyer TH, Brademann G, von zur Muhlen A (1996) Effect of fenfluramine on episodic ACTH and cortisol secretion. Clin Endocrinol (Oxf) 45:39–45. doi:10.1111/j.1365-2265.1996.tb02058.x CrossRef

23.

Cleare AJ, Forsling M, Bond AJ (1998) Neuroendocrine and hypothermic effects of 5-HT1A receptor stimulation with ipsapirone in healthy men: a placebo-controlled study. Int Clin Psychopharmacol 13:23–32. doi:10.1097/00004850-199801000-00004 PubMedCrossRef

24.

Meltzer HY, Maes M (1994) Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 35:316–323. doi:10.1016/0006-3223(94)90035-3 PubMedCrossRef

25.

Walsh AE, Ware CJ, Cowen PJ (1991) Lithium and 5-HT1A receptor sensitivity: a neuroendocrine study in healthy volunteers. Psychopharmacology (Berl) 105:568–572. doi:10.1007/BF02244382 CrossRef

26.

Rausch JL, Stahl SM, Hauger RL (1990) Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients. Biol Psychiatry 28:73–78. doi:10.1016/0006-3223(90)90434-4 PubMedCrossRef

27.

Sagud M, Pivac N, Muck-Seler D, Jakovljevic M, Mihaljevic-Peles A, Korsic M (2002) Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45:139–143. doi:10.1159/000054954 PubMedCrossRef

28.

Pitchot W, Wauthy J, Hansenne M et al (2002) Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers. Psychopharmacology (Berl) 164:27–32. doi:10.1007/s00213-002-1177-0 CrossRef

29.

Bhagwagar Z, Hafizi S, Cowen PJ (2002) Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology (Berl) 163:118–120. doi:10.1007/s00213-002-1149-4 CrossRef

30.

Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG (2005) Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology (Berl) 178:268–275. doi:10.1007/s00213-004-2006-4 CrossRef

31.

Berlin I, Warot D, Legout V, Guillemant S, Schollnhammer G, Puech AJ (1998) Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther 63:428–436. doi:10.1016/S0009-9236(98)90038-8 PubMedCrossRef

32.

Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME (1999) 5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 20:628–639. doi:10.1016/S0893-133X(98)00106-7 PubMedCrossRef

33.

Torpy DJ, Grice JE, Hockings GI, Walters MM, Crosbie GV, Jackson RV (1997) Diurnal effects of fluoxetine and naloxone on the human hypothalamic-pituitary-adrenal axis. Clin Exp Pharmacol Physiol 24:421–423. doi:10.1111/j.1440-1681.1997.tb01213.x PubMedCrossRef

34.

Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P (1997) Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 22:261–267. doi:10.1016/S0306-4530(97)00002-4 PubMedCrossRef

35.

de la Torre R, Farre M, Roset PN et al (2000) Pharmacology of MDMA in humans. Ann N Y Acad Sci 914:225–237PubMed

36.

Gouzoulis-Mayfrank E, Thelen B, Habermeyer E et al (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142:41–50 doi:10.1007/s002130050860 CrossRef

37.

Feuchtl A, Bagli M, Stephan R et al (2004) Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 37:180–188. doi:10.1055/s-2004-827175 PubMedCrossRef

38.

Monteleone P (1991) Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels. Neuropsychopharmacology 5:61–64PubMed

39.

Costa A, Martignoni E, Blandini F, Petraglia F, Genazzani AR, Nappi G (1993) Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans. Clin Neuropharmacol 16:127–138. doi:10.1097/00002826-199304000-00005 PubMedCrossRef

40.

Jezova D, Vigas M (1988) Apomorphine injection stimulates beta-endorphin, adrenocorticotropin, and cortisol release in healthy man. Psychoneuroendocrinology 13:479–485. doi:10.1016/0306-4530(88)90033-9 PubMedCrossRef

41.

Thorner MO, Ryan SM, Wass JA et al (1978) Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man. J Clin Endocrinol Metab 47:372–378PubMed

42.

Nishida S, Matsuki M, Nagase Y et al (1983) Stress-mediated effect of metoclopramide on cortisol secretion in man. J Clin Endocrinol Metab 56:839–843PubMed

43.

Staessen J, Fiocchi R, Bouillon R et al (1985) Differential responses of plasma aldosterone, cortisol and adrenocorticotropin to two dopamine receptor antagonists. Methods Find Exp Clin Pharmacol 7:523–527PubMed

44.

Coiro V, Volpi R, Capretti L et al (1990) 5-HT1-, but not 5-HT2-serotonergic, M1-, M2-muscarinic cholinergic or dopaminergic receptors mediate the ACTH/cortisol response to metoclopramide in man. Horm Res 33:233–238PubMed

45.

Jakovljevic M, Pivac N, Mihaljevic-Peles A et al (2007) The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog Neuropsychopharmacol Biol Psychiatry 31:399–402. doi:10.1016/j.pnpbp.2006.10.007 PubMedCrossRef

46.

Seki K (1989) Variability of cortisol and adrenocorticotropic hormone responses to metoclopramide during the menstrual cycle. Gynecol Obstet Invest 27:201–203PubMedCrossRef

47.

Joyce PR, Donald RA, Nicholls MG, Livesey JH, Abbott RM (1986) Endocrine and behavioral responses to methylphenidate in normal subjects. Biol Psychiatry 21:1015–1023. doi:10.1016/0006-3223(86)90282-9 PubMedCrossRef

48.

Brown WA, Williams BW (1976) Methylphenidate increases serum growth hormone concentrations. J Clin Endocrinol Metab 43:937–939PubMed

49.

Müller T, Muhlack S (2007) Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease. Clin Neuropharmacol 30:101–106. doi:10.1097/01.WNF.0000240954.72186.91 PubMedCrossRef

50.

Cohrs S, Roher C, Jordan W et al (2006) The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 185:11–18. doi:10.1007/s00213-005-0279-x CrossRef

51.

Heesch CM, Negus BH, Keffer JH, Snyder RW II, Risser RC, Eichhorn EJ (1995) Effects of cocaine on cortisol secretion in humans. Am J Med Sci 310:61–64. doi:10.1097/00000441-199508000-00004 PubMedCrossRef

52.

Pende A, Musso NR, Montaldi ML, Arzese M, Vergassola C, Devilla L (1987) Interaction between morphine, an opioid agonist, and clonidine, an alpha-adrenergic agonist, on the regulation of anterior pituitary hormone secretion in normal male subjects. Biomed Pharmacother 41:243–247PubMed

53.

Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Pucilowska J, Wierzbicki M, Jeske W (1988) Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity. Eur J Clin Pharmacol 35:115–121. doi:10.1007/BF00609239 PubMedCrossRef

54.

Baranowska B (1990) The effect of clonidine on hormone release mediated through activation of opiate receptors. Cardiovasc Drugs Ther 4:1113–1117. doi:10.1007/BF01856507 PubMedCrossRef

55.

Munoz-Hoyos A, Fernandez-Garcia JM, Molina-Carballo A et al (2000) Effect of clonidine on plasma ACTH, cortisol and melatonin in children. J Pineal Res 29:48–53. doi:10.1034/j.1600-079X.2000.290107.x PubMedCrossRef

56.

Krystal JH, McDougle CJ, Woods SW, Price LH, Heninger GR, Charney DS (1992) Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology (Berl) 108:313–319. doi:10.1007/BF02245117 CrossRef

57.

Schule C, Baghai T, Schmidbauer S, Bidlingmaier M, Strasburger CJ, Laakmann G (2004) Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 29:185–200. doi:10.1016/S0306-4530(03)00022-2 PubMedCrossRef

58.

Tse WS, Bond AJ (2005) Sex differences in cortisol response to reboxetine. J Psychopharmacol 19:46–50. doi:10.1177/0269881105048896 PubMedCrossRef

59.

Jacobs D, Silverstone T, Rees L (1989) The neuroendocrine response to oral dextroamphetamine in normal subjects. Int Clin Psychopharmacol 4:135–147PubMedCrossRef

60.

Sachar EJ, Halbreich U, Asnis GM, Nathan RS, Halpern FS, Ostrow L (1981) Paradoxical cortisol responses to dextroamphetamine in endogenous depression. Arch Gen Psychiatry 38:1113–1117PubMed

61.

Auernhammer CJ, Stalla GK, Lange M, Pfeiffer A, Müller OA (1992) Effects of loperamide on the human hypothalamo-pituitary-adrenal axis in vivo and in vitro. J Clin Endocrinol Metab 75:552–557. doi:10.1210/jc.75.2.552 PubMedCrossRef

62.

Delitala G, Grossman A, Besser M (1983) Differential effects of opiate peptides and alkaloids on anterior pituitary hormone secretion. Neuroendocrinology 37:275–279PubMedCrossRef

63.

Pende A, Musso NR, Montaldi ML, Pastorino G, Arzese M, Devilla L (1986) Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. Biomed Pharmacother 40:178–182PubMed

64.

Garland EJ, Zis AP (1989) Effect of codeine and oxazepam on afternoon cortisol secretion in men. Psychoneuroendocrinology 14:397–402. doi:10.1016/0306-4530(89)90009-7 PubMedCrossRef

65.

Rasheed A, Tareen IA (1995) Effects of heroin on thyroid function, cortisol and testosterone level in addicts. Pol J Pharmacol 47:441–444PubMed

66.

Zis AP, Remick RA, Clark CM, Goldner E, Grant BE, Brown GM (1989) Effect of morphine on cortisol and prolactin secretion in anorexia nervosa and depression. Clin Endocrinol (Oxf) 30:421–427CrossRef

67.

Allolio B, Winkelmann W, Hipp FX, Kaulen D, Mies R (1982) Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion. J Clin Endocrinol Metab 55:1–7PubMed

68.

Demura R, Suda T, Wakabayashi I et al (1981) Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33–824) in normal subjects and patients with pituitary diseases. J Clin Endocrinol Metab 52:263–266PubMed

69.

Bernini GP, Argenio GF, Cerri F, Franchi F (1994) Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest 17:799–804PubMed

70.

Ciampelli M, Guido M, Cucinelli F, Cinque B, Barini A, Lanzone A (2000) Hypothalamic-pituitary-adrenal axis sensitivity to opioids in women with polycystic ovary syndrome. Fertil Steril 73:712–717. doi:10.1016/S0015-0282(99)00602-0 PubMedCrossRef

71.

Banki CM, Arato M (1987) Multiple hormonal responses to morphine: relationship to diagnosis and dexamethasone suppression. Psychoneuroendocrinology 12:3–11. doi:10.1016/0306-4530(87)90016-3 PubMedCrossRef

72.

Ur E, Wright DM, Bouloux PM, Grossman A (1997) The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 120:781–784. doi:10.1038/sj.bjp.0700971 PubMedCrossRef

73.

Uhart M, Chong RY, Oswald L, Lin PI, Wand GS (2006) Gender differences in hypothalamic-pituitary-adrenal (HPA) axis reactivity. Psychoneuroendocrinology 31:642–652. doi:10.1016/j.psyneuen.2006.02.003 PubMedCrossRef

74.

Mendelson JH, Mello NK, Cristofaro P, Skupny A, Ellingboe J (1986) Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function. Pharmacol Biochem Behav 24:309–313. doi:10.1016/0091-3057(86)90356-4 PubMedCrossRef

75.

Geer EB, Landman RE, Wardlaw SL, Conwell IM, Freda PU (2005) Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene. Pituitary 8:115–122. doi:10.1007/s11102-005-5227-6 PubMedCrossRef

76.

Coiro V, d’Amato L, Marchesi C et al (1990) Luteinizing hormone and cortisol responses to naloxone in normal weight women with bulimia. Psychoneuroendocrinology 15:463–470. doi:10.1016/0306-4530(90)90069-L PubMedCrossRef

77.

Delitala G, Giusti M, Borsi L et al (1981) Effects of a Met-enkephalin analogue and naloxone infusion on anterior pituitary hormone secretion in acromegaly. Horm Res 15:88–98 PubMed

78.

Guido M, Ciampelli M, Fulghesu AM et al (1999) Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome. Fertil Steril 71:462–467. doi:10.1016/S0015-0282(98)00470-1 PubMedCrossRef

79.

Kemper A, Koalick F, Thiele H, Retzow A, Rathsack R, Nickel B (1990) Cortisol and beta-endorphin response in alcoholics and alcohol abusers following a high naloxone dosage. Drug Alcohol Depend 25:319–326. doi:10.1016/0376-8716(90)90158-B PubMedCrossRef

80.

Michelson D, Altemus M, Galliven E, Hill L, Greenberg BD, Gold P (1996) Naloxone-induced pituitary-adrenal activation does not differ in patients with depression, obsessive compulsive disorder, and healthy controls. Neuropsychopharmacology 15:207–212. doi:10.1016/0893-133X(95)00210-5 PubMedCrossRef

81.

Elias AN, Gwinup G, Valenta LJ (1981) Effects of valproic acid, naloxone and hydrocortisone in Nelson’s syndrome and Cushing’s disease. Clin Endocrinol (Oxf) 15:151–154CrossRef

82.

Tariot PN, Upadhyaya A, Sunderland T et al (1999) Physiologic and neuroendocrine responses to intravenous naloxone in subjects with Alzheimer’s disease and age-matched controls. Biol Psychiatry 46:412–419. doi:10.1016/S0006-3223(98)00329-1 PubMedCrossRef

83.

Volpi R, Caffarra P, Marcato A et al (1991) Reduced ACTH/cortisol responses to naloxone in men with Parkinson’s disease. J Neural Transm Park Dis Dement Sect 3:127–132. doi:10.1007/BF02260887 PubMedCrossRef

84.

Lanzone A, Guido M, Ciampelli M et al (1996) Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone. Clin Endocrinol (Oxf) 45:73–77. doi:10.1111/j.1365-2265.1996.tb02062.x CrossRef

85.

O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 160:19–29. doi:10.1007/s002130100919 CrossRef

86.

Delva NJ, Brooks DL, Franklin M et al (2002) Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects. J Psychiatry Neurosci 27:429–437PubMed

87.

Invitti C, Danesi L, Dubini A, Cavagnini F (1988) Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients. Acta Endocrinol (Copenh) 118:381–388

88.

Kritzler RK, Vining EP, Plotnick LP (1983) Sodium valproate and corticotropin suppression in the child treated for seizures. J Pediatr 102:142–143. doi:10.1016/S0022-3476(83)80313-8 PubMedCrossRef

89.

Cavagnini F, Invitti C, Polli EE (1984) Sodium valproate in Cushing’s disease. Lancet 2(8395):162–163PubMedCrossRef

90.

Flück CE, Yaworsky DC, Miller WL (2005) Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia 46:444–448. doi:10.1111/j.0013-9580.2005.38404.x PubMedCrossRef

91.

Chappell KA, Markowitz JS, Jackson CW (1999) Is valproate pharmacotherapy associated with polycystic ovaries? Ann Pharmacother 33:1211–1216. doi:10.1345/aph.19096 PubMedCrossRef

92.

Beary MD, Lacey JH, Bhat AV (1983) The neuro-endocrine impact of 3-hydroxy-diazepam (temazepam) in women. Psychopharmacology (Berl) 79:295–297. doi:10.1007/BF00433404 CrossRef

93.

Risby ED, Hsiao JK, Golden RN, Potter WZ (1989) Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects. Psychopharmacology (Berl) 99:508–514. doi:10.1007/BF00589900 CrossRef

94.

Mussig K, Friess E, Wudy SA, Morike K, Haring HU, Overkamp D (2006) Secondary adrenal failure due to long-term treatment with flunitrazepam. Clin Endocrinol (Oxf) 65:549–550. doi:10.1111/j.1365-2265.2006.02622.x CrossRef

95.

Risch SC, Janowsky DS, Mott MA et al (1986) Central and peripheral cholinesterase inhibition: effects on anterior pituitary and sympathomimetic function. Psychoneuroendocrinology 11:221–230. doi:10.1016/0306-4530(86)90057-0 PubMedCrossRef

96.

Peskind ER, Raskind MA, Wingerson D et al (1996) Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer’s disease and gender. Biol Psychiatry 40:61–68. doi:10.1016/0006-3223(95)00318-5 PubMedCrossRef

97.

Kumar V, Smith RC, Sherman KA et al (1988) Cortisol responses to cholinergic drugs in Alzheimer’s disease. Int J Clin Pharmacol Ther Toxicol 26:471–476PubMed

98.

Asthana S, Raffaele KC, Greig NH, Schapiro MB, Blackman MR, Soncrant TT (1999) Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 13:102–108. doi:10.1097/00002093-199904000-00008 PubMedCrossRef

99.

Rubin RT, O’Toole SM, Rhodes ME, Sekula LK, Czambel RK (1999) Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects. Psychiatry Res 89:1–20. doi:10.1016/S0165-1781(99)00085-2 PubMedCrossRef

100.

Peskind ER, Raskind MA, Wingerson D et al (1995) Enhanced hypothalamic-pituitary-adrenocortical axis responses to physostigmine in normal aging. J Gerontol A Biol Sci Med Sci 50:M114–M120PubMed

101.

Rubin RT, Rhodes ME, Miller TH, Jakab RL, Czambel RK (2006) Sequence of pituitary-adrenal cortical hormone responses to low-dose physostigmine administration in young adult women and men. Life Sci 79:2260–2268. doi:10.1016/j.lfs.2006.07.023 PubMedCrossRef

102.

Laakmann G, Schoen HW, Blaschke D, Wittmann M (1985) Dose-dependent growth hormone, prolactin and cortisol stimulation after i.v. administration of desimipramine in human subjects. Psychoneuroendocrinology 10:83–93. doi:10.1016/0306-4530(85)90042-3 PubMedCrossRef

103.

Nutt D, Middleton H, Franklin M (1987) The neuroendocrine effects of oral imipramine. Psychoneuroendocrinology 12:367–375. doi:10.1016/0306-4530(87)90065-5 PubMedCrossRef

104.

Laakmann G, Wittmann M, Gugath M et al (1984) Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis. Psychopharmacology (Berl) 84:66–70. doi:10.1007/BF00432027 CrossRef

105.

Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ (1989) The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab 68:632–637PubMed

106.

Schule C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G (2002) The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 163:95–101. doi:10.1007/s00213-002-1148-5 CrossRef

107.

Schule C, Sighart C, Hennig J, Laakmann G (2006) Mirtazapine inhibits salivary cortisol concentrations in anorexia nervosa. Prog Neuropsychopharmacol Biol Psychiatry 30:1015–1019. doi:10.1016/j.pnpbp.2006.03.023 PubMedCrossRef

108.

Laakmann G, Hennig J, Baghai T, Schule C (2004) Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. Ann N Y Acad Sci 1032:279–282. doi:10.1196/annals.1314.038 PubMedCrossRef

109.

Lissoni P, Brivio F, Fumagalli L et al (2007) Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia. In vivo 21:647–650PubMed

110.

Corssmit EP, Heijligenberg R, Endert E, Ackermans MT, Sauerwein HP, Romijn JA (1996) Endocrine and metabolic effects of interferon-alpha in humans. J Clin Endocrinol Metab 81:3265–3269. doi:10.1210/jc.81.9.3265 PubMedCrossRef

111.

Angioni S, Iori G, Cellini M et al (1992) Acute beta-interferon or thymopentin administration increases plasma growth hormone and cortisol levels in children. Acta Endocrinol (Copenh) 127:237–241

112.

de Metz J, Sprangers F, Endert E et al (1999) Interferon-gamma has immunomodulatory effects with minor endocrine and metabolic effects in humans. J Appl Physiol 86:517–522PubMed

113.

Nolten WE, Goldstein D, Lindstrom M et al (1993) Effects of cytokines on the pituitary-adrenal axis in cancer patients. J Interferon Res 13:349–357PubMed

114.

Curti BD, Urba WJ, Longo DL et al (1996) Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer. J Immunother Emphasis Tumor Immunol 19:142–148PubMed

115.

Muller H, Hiemke C, Hammes E, Hess G (1992) Sub-acute effects of interferon-alpha 2 on adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in humans. Psychoneuroendocrinology 17:459–465. doi:10.1016/0306-4530(92)90004-Q PubMedCrossRef

116.

Spath-Schwalbe E, Hansen K, Schmidt F et al (1998) Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 83:1573–1579. doi:10.1210/jc.83.5.1573 PubMedCrossRef

117.

Lissoni P, Rovelli F, Tisi E et al (1992) Endocrine effects of human recombinant interleukin-3 in cancer patients. Int J Biol Markers 7:230–233PubMed

118.

Giavoli C, Libé R, Corbetta S et al (2004) Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 89:5397–5401. doi:10.1210/jc.2004-1114 PubMedCrossRef

119.

Mishra SK, Gupta N, Goswami R (2007) Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab 92:1693–1696. doi:10.1210/jc.2006-2090 PubMedCrossRef

120.

Tsatsoulis A, Johnson EO, Kalogera CH, Seferiadis K, Tsolas O (2000) The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol 142:231–235. doi:10.1530/eje.0.1420231 PubMedCrossRef

121.

Malik KJ, Wakelin K, Dean S, Cove DH, Wood PJ (1996) Cushing’s syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate. Ann Clin Biochem 33:187–189PubMed

122.

Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K (2003) Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis. Cancer Chemother Pharmacol 52:482–486. doi:10.1007/s00280-003-0697-6 PubMedCrossRef

123.

Lundgren S, Lonning PE, Utaaker E, Aakvaag A, Kvinnsland S (1990) Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer – I. General findings. J Steroid Biochem 36:99–104. doi:10.1016/0022-4731(90)90118-C PubMedCrossRef

124.

Matin K, Egorin MJ, Ballesteros MF et al (2002) Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. Cancer Chemother Pharmacol 50:179–185. doi:10.1007/s00280-002-0484-9 PubMedCrossRef

125.

Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM (2006) High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 29:136–140PubMed

126.

Leinung MC, Liporace R, Miller CH (1995) Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 122:843–845PubMed

127.

Clerico A, Minervini R, Del Chicca MG, Barsantini S, Fiorentini L (1984) Elevated free cortisol plasma levels in patients with prostatic carcinoma undergoing treatment with estrogens. Int J Clin Pharmacol Res 4:335–339PubMed

128.

Qureshi AC, Bahri A, Breen LA et al (2007) The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf) 66:632–635. doi:10.1111/j.1365-2265.2007.02784.x CrossRef

129.

Genazzani AR, Lombardi I, Borgioli G et al (2003) Adrenal function under long-term raloxifene administration. Gynecol Endocrinol 17:159–168. doi:10.1080/713603211 PubMedCrossRef

130.

Späth-Schwalbe E, Piroth L, Pietrowsky R, Born J, Fehm HL (1988) Stimulation of the pituitary adrenocortical system in man by cerulein, a cholecystokinin-8-like peptide. Clin Physiol Biochem 6:316–320PubMed

131.

Schule C, Baghai T, Sauer N, Laakmann G (2004) Endocrinological effects of high-dose Hypericum perforatum extract WS 5570 in healthy subjects. Neuropsychobiology 49:58–63. doi:10.1159/000076411 PubMedCrossRef

132.

Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F (2000) The desmopressin test in the differential diagnosis between Cushing’s disease and pseudo-Cushing states. J Clin Endocrinol Metab 85:3569–3574. doi:10.1210/jc.85.10.3569 PubMedCrossRef

133.

Schoneshofer M, Fenner A, Altinok G, Dulce HJ (1980) Specific and practicable assessment of urinary free cortisol by combination of automatic high-pressure liquid chromatography and radioimmunoassay. Clin Chim Acta 106:63–73. doi:10.1016/0009-8981(80)90375-7 PubMedCrossRef

134.

Fink RS, Pierre LN, Daley-Yates PT, Richards DH, Gibson A, Honour JW (2002) Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation. J Clin Endocrinol Metab 87:4541–4546. doi:10.1210/jc.2002-020287 PubMedCrossRef

135.

Turpeinen U, Markkanen H, Valimaki M, Stenman UH (1997) Determination of urinary free cortisol by HPLC. Clin Chem 43:1386–1391PubMed

136.

Findling JW, Pinkstaff SM, Shaker JL, Raff H, Nelson JC (1998) Pseudohypercortisoluria: spurious elevation of urinary cortisol due to carbamazepine. Endocrinologist 8:51–54. doi:10.1097/00019616-199803000-00001 CrossRef

137.

Taylor RL, Machacek D, Singh RJ (2002) Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin Chem 48:1511–1519PubMed

138.

Meikle AW, Findling J, Kushnir MM, Rockwood AL, Nelson GJ, Terry AH (2003) Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography. J Clin Endocrinol Metab 88:3521–3524. doi:10.1210/jc.2003-030234 PubMedCrossRef

139.

Schurmeyer TH, Brademann G, von zur Muhlen A (1996) Effect of fenfluramine on episodic ACTH and cortisol secretion. Clin Endocrinol (Oxf) 45:39–45. doi:10.1111/j.1365-2265.1996.tb02058.x CrossRef

140.

Razenberg AJ, Elte JW, Rietveld AP, van Zaanen HC, Cabezas MC (2007) A ‘smart’ type of Cushing’s syndrome. Eur J Endocrinol 157:779–781. doi:10.1530/EJE-07-0538 PubMedCrossRef

141.

Lopez AL, Kathol RG, Noyes R Jr (1990) Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinology 15:23–28. doi:10.1016/0306-4530(90)90043-9 PubMedCrossRef

142.

Vicennati V, Ceroni L, Gagliardi L et al (2004) Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity. J Endocrinol Invest 27:541–547PubMed

143.

Schule C, Baghai T, Rackwitz C, Laakmann G (2003) Influence of mirtazapine on urinary free cortisol excretion in depressed patients. Psychiatry Res 120:257–264. doi:10.1016/S0165-1781(03)00204-X PubMedCrossRef

144.

Prinz P, Bailey S, Moe K, Wilkinson C, Scanlan J (2001) Urinary free cortisol and sleep under baseline and stressed conditions in healthy senior women: effects of estrogen replacement therapy. J Sleep Res 10:19–26. doi:10.1046/j.1365-2869.2001.00236.x PubMedCrossRef

145.

Ruokonen A, Lund L, Nummi S, Alapiessa U, Viinikka L (1982) Effects of two oral contraceptive combinations, 0.125 mg desogestrel + 0.050 mg ethinylestradiol and 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol on the adrenal function of healthy female volunteers. Eur J Obstet Gynecol Reprod Biol 13:259–265. doi:10.1016/0028-2243(82)90107-1 PubMedCrossRef

146.

MacKenzie MA, Hoefnagels WH, Jansen RW, Benraad TJ, Kloppenborg PW (1990) The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J Clin Endocrinol Metab 70:1637–1643PubMed

147.

Agha A, Monson JP (2007) Modulation of glucocorticoid metabolism by the growth hormone–IGF-1 axis. Clin Endocrinol (Oxf) 66:459–465

148.

Ma RC, Chan WB, So WY, Tong PC, Chan JC, Chow CC (2005) Carbamazepine and false positive dexamethasone suppression tests for Cushing’s syndrome. BMJ 330:299–300. doi:10.1136/bmj.330.7486.299 PubMedCrossRef

149.

Debrunner J, Schmid C, Schneemann M (2002) Falsely positive dexamethasone suppression test in a patient treated with phenytoin to prevent seizures due to nocardia brain abscesses. Swiss Med Wkly 132:267PubMed

150.

Kyriazopoulou V, Vagenakis AG (1992) Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy. J Clin Endocrinol Metab 75:315–317. doi:10.1210/jc.75.1.315 PubMedCrossRef

151.

Keitner GI, Fruzzetti AE, Miller IW, Norman WH, Brown WA (1989) The effect of anticonvulsants on the dexamethasone suppression test. Can J Psychiatry 34:441–443PubMed

152.

Putignano P, Kaltsas GA, Satta MA, Grossman AB (1998) The effects of anti-convulsant drugs on adrenal function. Horm Metab Res 30:389–397PubMed

153.

Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 67:451–457. doi:10.1067/mcp.2000.106793 PubMedCrossRef

154.

Wenk M, Todesco L, Krahenbuhl S (2004) Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 57:495–499. doi:10.1111/j.1365-2125.2003.02049.x PubMedCrossRef

155.

Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B (1997) Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome – recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 34:222–229PubMed

156.

Charles GA, Orsulak PJ, Rush AJ, Fulton CL (1995) Arecoline reverses dexamethasone suppression of cortisol in normal males: a pilot study. Biol Psychiatry 37:811–816. doi:10.1016/0006-3223(94)00215-O PubMedCrossRef

157.

Berger M, Doerr P, von Zerssen D (1984) Physostigmine’s influence on DST results. Am J Psychiatry 141:469–470PubMed

158.

Maes M, Van Gastel A, Meltzer HY, Cosyns P, Blockx P, Desnyder R (1996) Acute administration of buspirone increases the escape of hypothalamic-pituitary-adrenal-axis hormones from suppression by dexamethasone in depression. Psychoneuroendocrinology 21:67–81. doi:10.1016/0306-4530(95)00028-3 PubMedCrossRef

159.

Gottfries CG, Nyth AL (1991) Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann N Y Acad Sci 640:276–279PubMed

160.

Bschor T, Baethge C, Adli M et al (2003) Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety 17:43–48. doi:10.1002/da.10078 PubMedCrossRef

161.

Kin NM, Nair NP, Amin M et al (1997) The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline. Biol Psychiatry 42:925–931. doi:10.1016/S0006-3223(97)00158-3 PubMedCrossRef

162.

Dommisse CS, Hayes PE, Kwentus JA (1985) Effect of estrogens on the dexamethasone suppression test in nondepressed women. J Clin Psychopharmacol 5:315–319PubMed

163.

Tiller JW, Maguire KP, Schweitzer I et al (1988) The dexamethasone suppression test: a study in a normal population. Psychoneuroendocrinology 13:377–384. doi:10.1016/0306-4530(88)90044-3 PubMedCrossRef

164.

Gozansky WS, Lynn JS, Laudenslager ML, Kohrt WM (2005) Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic–pituitary–adrenal axis activity. Clin Endocrinol (Oxf) 63:336–341. doi:10.1111/j.1365-2265.2005.02349.x CrossRef

165.

Schmid DA, Wichniak A, Uhr M et al (2006) Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 31:832–844. doi:10.1038/sj.npp.1300923 PubMedCrossRef

166.

Jarrett DB, Pollock B, Miewald JM, Kupfer DJ (1991) Acute effect of intravenous clomipramine upon sleep-related hormone secretion in depressed outpatients and healthy control subjects. Biol Psychiatry 29:3–14. doi:10.1016/0006-3223(91)90206-2 PubMedCrossRef

167.

Skene DJ, Bojkowski CJ, Arendt J (1994) Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 37:181–186PubMed

168.

Steiger A, Benkert O, Holsboer F (1994) Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men. Neuropsychobiology 30:101–105PubMedCrossRef

169.

Mann K, Rossbach W, Müller MJ et al (2006) Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31:256–264. doi:10.1016/j.psyneuen.2005.08.005 PubMedCrossRef

170.

Dodt C, Kern W, Fehm HL, Born J (1993) Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology 58:570–574PubMedCrossRef

171.

Steiger A, Benkert O, Wöhrmann S, Steinseifer D, Holsboer F (1989) Effects of trimipramine on sleep EEG, penile tumescence and nocturnal hormonal secretion. A long-term study in 3 normal controls. Neuropsychobiology 21:71–75PubMedCrossRef

172.

Wiegand M, Berger M (1989) Action of trimipramine on sleep and pituitary hormone secretion. Drugs 38(Suppl 1):35–42. discussion 49–50PubMedCrossRef

173.

Sonntag A, Rothe B, Guldner J, Yassouridis A, Holsboer F, Steiger A (1996) Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression. 4:1–13. doi:10.1002/(SICI)1522-7162(1996)4:1<1::AID-DEPR1>3.0.CO;2-S PubMedCrossRef

174.

Facchinetti F, Volpe A, Farci G et al (1985) Hypothalamus-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend 15:361–366. doi:10.1016/0376-8716(85)90014-6 PubMedCrossRef

175.

Thakore JH, Barnes C, Joyce J, Medbak S, Dinan TG (1997) Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Res 73:27–32. doi:10.1016/S0165-1781(97)00106-6 PubMedCrossRef

176.

Hellman L, Yoshida K, Zumoff B, Levin J, Kream J, Fukushima DK (1976) The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 42:912–917PubMed

177.

Leis D, Bottermann P, Ermler R, Henderkott U, Glück H (1980) The influence of high doses of oral medroxyprogesterone acetate on glucose tolerance, serum insulin levels and adrenal response to ACTH. A study of 17 patients under treatment for endometrial cancer. Arch Gynecol 230:9–13. doi:10.1007/BF02108593 PubMedCrossRef

178.

Subramanian S, Goker H, Kanji A, Sweeney H (1997) Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med 157:1008–1011. doi:10.1001/archinte.157.9.1008 PubMedCrossRef

179.

Giavoli C, Bergamaschi S, Ferrante E et al (2008) Effect of growth hormone deficiency and recombinant hGH (rhGH) replacement on the hypothalamic-pituitary-adrenal axis in children with idiopathic isolated GH deficiency. Clin Endocrinol (Oxf) 68:247–251

180.

Trachtenberg J, Zadra J (1988) Steroid synthesis inhibition by ketoconazole: sites of action. Clin Invest Med 11:1–5PubMed

181.

Albert SG, DeLeon MJ, Silverberg AB (2001) Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit Care Med 29:668–670. doi:10.1097/00003246-200103000-00039 PubMedCrossRef

182.

Belkien L, Baumann J, Schirpai M, Oelkers W (1983) Propranolol enhances the effect of ACTH on plasma cortisol, but not on aldosterone in man. J Endocrinol Invest 6:341–345PubMed

183.

Kizildere S, Glück T, Zietz B, Schölmerich J, Straub RH (2003) During a corticotropin-releasing hormone test in healthy subjects, administration of a beta-adrenergic antagonist induced secretion of cortisol and dehydroepiandrosterone sulfate and inhibited secretion of ACTH. Eur J Endocrinol 148:45–53. doi:10.1530/eje.0.1480045 PubMedCrossRef

184.

Ljung T, Ahlberg AC, Holm G et al (2001) Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 250:219–224. doi:10.1046/j.1365-2796.2001.00881.x PubMedCrossRef

185.

Tomori N, Suda T, Nakagami Y et al (1989) Adrenergic modulation of adrenocorticotropin responses to insulin-induced hypoglycemia and corticotropin-releasing hormone. J Clin Endocrinol Metab 68:87–93PubMed

186.

Arvat E, Maccagno B, Giordano R et al (2001) Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab 86:3176–3181. doi:10.1210/jc.86.7.3176 PubMedCrossRef

187.

Nishida S, Matsuki M, Adachi N et al (1987) Pituitary-adrenocortical response to metoclopramide in patients with acromegaly and prolactinoma: a clinical evaluation of catecholamine-mediated adrenocorticotropin secretion. J Clin Endocrinol Metab 64:995–1001PubMedCrossRef

188.

Gisslinger H, Svoboda T, Clodi M et al (1993) Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 57:489–495PubMedCrossRef

189.

Rittmaster RS, Cutler GB Jr, Sobel DO et al (1985) Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects. J Clin Endocrinol Metab 60:891–895PubMed

190.

Allolio B, Schulte HM, Deuss U, Kallabis D, Hamel E, Winkelman W (1987) Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol (Copenh) 114:509–514

191.

Michelson D, Galliven E, Hill L, Demitrack M, Chrousos G, Gold P (1997) Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. Clin Endocrinol Metab 82:2601–2606. doi:10.1210/jc.82.8.2601 CrossRef

192.

Korbonits M, Trainer PJ, Edwards R, Besser GM, Grossman AB (1995) Benzodiazepines attenuate the pituitary-adrenal responses to corticotrophin-releasing hormone in healthy volunteers, but not in patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 43:29–35CrossRef

Titel: Drugs and HPA axis
verfasst von: Alberto Giacinto Ambrogio
Francesca Pecori Giraldi
Francesco Cavagnini
Publikationsdatum: 01.06.2008
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 2/2008
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-008-0114-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Diagnosis of adult GH deficiency

Systemic illness

Dynamic testing in Cushing’s syndrome

Central hypothyroidism

Pituitary testing: a reappraisal